American journal of hypertension · 2026
Blood pressure parameters and cognitive decline and dementia after stroke or transient ischemic attack: results from the PROGRESS trial.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shajahan Sultana, Woodward Mark, Anderson Craig S, Carcel Cheryl, Chen Linan, Peters Ruth, Rådholm Karin, Harrap Stephen, Chalmers John, Harris Katie
Аннотация
BACKGROUND: Besides elevated mean systolic blood pressure (BP), BP variability, pulse pressure (PP), or mean arterial pressure (MAP) could be important targets for dementia prevention. This study investigated these associations in participants with stroke or transient ischemic attack from the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial.
METHODS: BP parameters were calculated from measurements for 18 months on six occasions. Risk of cognitive decline according to Mini-Mental State Examination scores and/or adjudicated dementia outcomes per 1-standard deviation higher for each BP parameter was calculated using modified Poisson regression models with a log link. Subgroup analysis was conducted by mild cognitive impairment (MCI) at baseline, sex, and stroke subtype.
RESULTS: Of 5128 participants recruited between May 1995 and November 1997, 567 (11.1%) developed cognitive decline/dementia after 4 (median) years of follow-up until 2001. For systolic BP (SBP), higher mean, maximum, cumulative load, and last measure were associated with higher risk of cognitive decline/dementia, but mean conferred the highest risk (relative risk 1.18, 95% confidence intervals [CIs] 1.06-1.31). For diastolic BP, higher mean, maximum, variability, cumulative load, slope, and last measure were associated, while load showed the strongest association (1.23, 95% CI 1.12-1.36). Only the mean PP was associated (1.11, 95% CI 1.00-1.24). For MAP, MAP load showed the strongest association (1.20, 95% CI 1.09-1.33). Systolic, diastolic, and MAP variability showed a higher risk in those without MCI.
CONCLUSIONS: Besides mean SBP, higher variability, cumulative load, slope, and last measures of diastolic BP, PP, and MAP were associated with increased risk of cognitive decline/dementia.
CLINICAL TRIAL REGISTRATION: This trial was not registered because enrollment began before July 1, 2005.
METHODS: BP parameters were calculated from measurements for 18 months on six occasions. Risk of cognitive decline according to Mini-Mental State Examination scores and/or adjudicated dementia outcomes per 1-standard deviation higher for each BP parameter was calculated using modified Poisson regression models with a log link. Subgroup analysis was conducted by mild cognitive impairment (MCI) at baseline, sex, and stroke subtype.
RESULTS: Of 5128 participants recruited between May 1995 and November 1997, 567 (11.1%) developed cognitive decline/dementia after 4 (median) years of follow-up until 2001. For systolic BP (SBP), higher mean, maximum, cumulative load, and last measure were associated with higher risk of cognitive decline/dementia, but mean conferred the highest risk (relative risk 1.18, 95% confidence intervals [CIs] 1.06-1.31). For diastolic BP, higher mean, maximum, variability, cumulative load, slope, and last measure were associated, while load showed the strongest association (1.23, 95% CI 1.12-1.36). Only the mean PP was associated (1.11, 95% CI 1.00-1.24). For MAP, MAP load showed the strongest association (1.20, 95% CI 1.09-1.33). Systolic, diastolic, and MAP variability showed a higher risk in those without MCI.
CONCLUSIONS: Besides mean SBP, higher variability, cumulative load, slope, and last measures of diastolic BP, PP, and MAP were associated with increased risk of cognitive decline/dementia.
CLINICAL TRIAL REGISTRATION: This trial was not registered because enrollment began before July 1, 2005.